洛匹那韦/利托那韦(LPV/r)是第一个上市的复合型蛋白酶抑制剂(PI),其问世时间长,安全性高,是儿童抗反转录病毒治疗的骨干药物。在婴幼儿身上,其药代动力学有特殊性。而关于该药在儿童病人的使用,也有一些新的研究,例如单药治疗、一天一次服药、双利托那韦激动的蛋白酶抑制剂联合、低剂量用药等。这些研究为临床应用提供了新的可能性。 Lopinavir / Ritonavir (LPV / r) is the first commercially available complex-type protease inhibitor (PI) that has been well established and safe for many years and has been used as the backbone drug in children’s antiretroviral therapy. In infants and young children, their pharmacokinetics have particularity. As for the use of this medicine in pediatric patients, there are also some new studies, such as monotherapy, once-daily medication, double-ritonavir-stimulated protease inhibitor combination, and low-dose medication. These studies provide new possibilities for clinical applications.